This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Innovation ETF (ARKK) Hits New 52-Week High
by Sweta Killa
Cathie Wood's ARKK hits a 52-week high after bold biotech moves, signaling renewed momentum in disruptive tech.
908 Devices (MASS) Upgraded to Buy: Here's What You Should Know
by Zacks Equity Research
908 Devices (MASS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
All You Need to Know About 908 Devices (MASS) Rating Upgrade to Buy
by Zacks Equity Research
908 Devices (MASS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Bet On 4 Low-Beta Stocks BWB, LRN, MASS & PM Despite Tariff Truce
by Nilanjan Banerjee
It is imperative to build a portfolio of low-beta stocks in a volatile market. Bridgewater Bancshares, Stride, 908 Devices, and Philip Morris are well-positioned to gain.
908 Devices Inc. (MASS) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
908 Devices (MASS) delivered earnings and revenue surprises of 18.52% and 2.99%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Inogen (INGN) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Inogen (INGN) delivered earnings and revenue surprises of 51.92% and 3.26%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Will Lucid Diagnostics Inc. (LUCD) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
Lucid Diagnostics (LUCD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
908 Devices Inc. (MASS) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
908 Devices (MASS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Avanos Medical (AVNS) Q1 Earnings and Revenues Top Estimates
by Zacks Equity Research
Avanos Medical (AVNS) delivered earnings and revenue surprises of 36.84% and 2.04%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
MTD Q1 Earnings Top Estimates, Sales Decline Y/Y, Shares Rise
by Zacks Equity Research
Mettler-Toledo International's Q1 results reflect growth in the Laboratory business, a decline in Industrial, and continued weakness in the Food Retail segment.
Buy 4 Low-Beta Stocks ANIP, LRN, MASS & CTGO as Tariff Woes Continue
by Nilanjan Banerjee
It is imperative to build a portfolio of low-beta stocks in a volatile market. ANI Pharmaceuticals, Stride, 908 Devices, & Contango are well-poised to gain.
The Zacks Analyst Blog Highlights Fidelity NASDAQ Composite Index ETF, ThredUp, 908 Devices, Logility Supply Chain, Palomar and EZCORP
by Zacks Equity Research
Fidelity NASDAQ Composite Index ETF, ThredUp, 908 Devices, Logility Supply Chain, Palomar and EZCORP are included in this Analyst Blog.
5 Top-Ranked Stocks of Nasdaq ETF Beating the Bear Market
by Sanghamitra Saha
The tech-focused Nasdaq officially entered bear market territory on Friday, falling over 20% from its December peak.
New Strong Buy Stocks for April 1st
by Zacks Equity Research
AFRM, TKOMY, FOLD, MASS and VFC have been added to the Zacks Rank #1 (Strong Buy) List on April 1, 2025.
Best Momentum Stocks to Buy for March 13th
by Zacks Equity Research
BK, TKOMY and MASS made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on March 13, 2025.
908 Devices Inc. (MASS) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
908 Devices (MASS) delivered earnings and revenue surprises of 8.57% and 10.03%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Teleflex (TFX) Surpasses Q4 Earnings Estimates
by Zacks Equity Research
Teleflex (TFX) delivered earnings and revenue surprises of 0.78% and 2.23%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Alphatec (ATEC) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Alphatec (ATEC) delivered earnings and revenue surprises of -27.78% and 1.94%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
908 Devices Inc. (MASS) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
908 Devices (MASS) delivered earnings and revenue surprises of 20.69% and 8.13%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Globus Medical (GMED) Beats Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Globus Medical (GMED) delivered earnings and revenue surprises of 27.69% and 3.44%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
908 Devices Inc. (MASS) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
908 Devices (MASS) delivered earnings and revenue surprises of 5.88% and 2.59%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
ClearPoint Neuro, Inc. (CLPT) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
ClearPoint Neuro (CLPT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Earnings Preview: 908 Devices Inc. (MASS) Q2 Earnings Expected to Decline
by Zacks Equity Research
908 Devices (MASS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Wall Street Analysts Predict a 133.69% Upside in 908 Devices (MASS): Here's What You Should Know
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 133.7% in 908 Devices (MASS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
908 Devices (MASS) Loses -9.95% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
by Zacks Equity Research
908 Devices (MASS) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.